<DOC>
	<DOC>NCT01470456</DOC>
	<brief_summary>Primary Objective: Participants Achieving an Objective Response Rate (Cheson 2007) Secondary Objectives: - Progression Free Survival - Overall Survival - Response Duration</brief_summary>
	<brief_title>Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>- The screening period = up to 4 weeks prior to the first administration of combined therapy - The treatment period = 3 months of combined therapy. A safety follow-up of 42 to 49 days after the last dose of treatment is planned for all patients. - The follow-up period: Patients who are not progressing at the end of study treatment will be followed until progression or initiation of another anti-lymphoma therapy. All patients will be followed for two years to evaluate survival.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Inclusion criteria: Histological diagnosis of Diffuse Large BCell Lymphoma (DLBCL) Relapsed or refractory after at least one standard treatment including rituximab CD19 and CD20 positive disease Exclusion criteria: No bidimensionally measurable lesion by CT scan (defined as presence of at least one tumor mass measuring &gt;1.5 x 1.5 cm) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>